Pediatric Promise: China Bets On Better Medicines Amid Three Child Policy Roll-Out
But Industry Incentives Still Limited
Executive Summary
As China's regulators renew moves to encourage the development of pediatric medicines, indication expansion may give health players a new growth engine, despite remaining policy challenges and lingering market uncertainties.
You may also be interested in...
Catch-22: Biotech Boom Brings Clinical Services, Regulatory Crunch In China
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.
China Hits Two Billion COVID Jabs But More Effective mRNA Shots Elude
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Emerging Biopharma’s Next First Launch Market: China?
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.